• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectis S.A. ADR (NQ: CLLS )

    2.990 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 90,809
    Open 2.890
    Bid (Size) 2.980 (3)
    Ask (Size) 3.100 (5)
    Prev. Close 2.990
    Today's Range 2.890 - 3.090
    52wk Range 0.9628 - 3.773
    Shares Outstanding 45,484,310
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
    From Cellectis Inc.
    Via GlobeNewswire
    CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023
    CLLS stock results show that Cellectis missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    -2.61%
    -2.61%
    1 Month
    +7.17%
    +7.17%
    3 Month
    +1.36%
    +1.36%
    6 Month
    +4.55%
    +4.55%
    1 Year
    +59.04%
    +59.04%

    More News

    Read More
    Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
    From Cellectis Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 6, 2023
    Via Benzinga
    Earnings Preview: Cellectis
    Via Benzinga
    Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis’ Shareholders Meeting to be Held on December 22, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
    Via InvestorPlace
    Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023
    From Cellectis Inc.
    Via GlobeNewswire
    Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Why Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?
    Via Benzinga
    Nasdaq Surges Over 100 Points Ahead Of Fed Decision; WeWork Shares Plunge
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    US Stocks Mixed; Private Sector Payrolls Increase Less Than Expected
    Via Benzinga
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.